Smith Salley Wealth Management raised its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 168,246 shares of the company’s stock after buying an additional 3,908 shares during the quarter. Merck & Co., Inc. makes up approximately 1.2% of Smith Salley Wealth Management’s holdings, making the stock its 26th largest holding. Smith Salley Wealth Management’s holdings in Merck & Co., Inc. were worth $19,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. Industrial Alliance Investment Management Inc. lifted its position in Merck & Co., Inc. by 2.6% during the 1st quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock worth $421,000 after acquiring an additional 80 shares during the last quarter. IRON Financial LLC increased its stake in shares of Merck & Co., Inc. by 4.6% in the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock worth $224,000 after purchasing an additional 80 shares during the period. Argent Capital Management LLC lifted its position in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock worth $1,302,000 after purchasing an additional 81 shares during the last quarter. Forza Wealth Management LLC boosted its stake in Merck & Co., Inc. by 0.8% during the 2nd quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock valued at $1,297,000 after purchasing an additional 82 shares during the period. Finally, Vista Investment Partners LLC grew its holdings in Merck & Co., Inc. by 2.0% in the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock valued at $516,000 after buying an additional 82 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.
Merck & Co., Inc. Price Performance
Shares of MRK stock opened at $103.98 on Friday. Merck & Co., Inc. has a 1 year low of $99.80 and a 1 year high of $134.63. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80. The firm’s 50 day moving average is $113.52 and its 200-day moving average is $121.63. The firm has a market capitalization of $263.36 billion, a price-to-earnings ratio of 19.29, a PEG ratio of 1.52 and a beta of 0.39.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 31st. UBS Group decreased their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Bank of America cut their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Evercore ISI raised Merck & Co., Inc. to a “strong-buy” rating in a research report on Tuesday, July 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.50.
Check Out Our Latest Analysis on MRK
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- Find and Profitably Trade Stocks at 52-Week Lows
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is a Stock Market Index and How Do You Use Them?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Earnings Per Share Calculator: How to Calculate EPS
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.